China Pharma Holdings, Inc. SEC filings CPHI
China Pharma Holdings, Inc. has 426 filings in SEC EDGAR's recent list, going back to Feb 15, 2000. Its latest annual report, Form 10-K, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jul 22, 2026 (material agreement, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| PRE 14A | Preliminary proxy statement | Oct 30, 2026 | Oct 30, 2026 |
| DEF 14A | Proxy statement | Nov 14, 2025 | Dec 30, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 4, 2025 | Nov 4, 2025 |
| DEF 14A | Proxy statement | Nov 12, 2024 | Dec 22, 2024 |
| PRE 14A | Preliminary proxy statement | Nov 1, 2024 | Nov 1, 2024 |
| DEF 14A | Proxy statement | Nov 7, 2023 | Dec 18, 2023 |
| PRE 14A | Preliminary proxy statement | Oct 27, 2023 | Oct 27, 2023 |
| DEF 14A | Proxy statement | Nov 14, 2022 | Dec 28, 2022 |
| PRE 14A | Preliminary proxy statement | Nov 4, 2022 | Dec 28, 2022 |
| DEFA14A | Additional proxy material | Nov 15, 2021 | — |
| DEF 14A | Proxy statement | Nov 15, 2021 | Dec 27, 2021 |
| DEFA14A | Additional proxy material | Nov 16, 2020 | — |
| DEF 14A | Proxy statement | Nov 16, 2020 | Dec 28, 2020 |
| DEFA14A | Additional proxy material | Nov 6, 2019 | — |
| DEF 14A | Proxy statement | Nov 6, 2019 | Dec 19, 2019 |
| DEFA14A | Additional proxy material | Oct 25, 2018 | — |
| DEF 14A | Proxy statement | Oct 25, 2018 | Dec 5, 2018 |
| DEFA14A | Additional proxy material | Nov 3, 2017 | — |
| DEF 14A | Proxy statement | Nov 3, 2017 | Dec 14, 2017 |
| DEFA14A | Additional proxy material | Oct 28, 2016 | — |
| DEF 14A | Proxy statement | Oct 28, 2016 | Dec 8, 2016 |
| DEFA14A | Additional proxy material | Oct 29, 2015 | — |
| DEF 14A | Proxy statement | Oct 29, 2015 | Dec 8, 2015 |
| DEF 14A | Proxy statement | Nov 20, 2014 | Dec 29, 2014 |
| DEFA14A | Additional proxy material | Nov 6, 2013 | — |
| DEF 14A | Proxy statement | Nov 6, 2013 | Dec 16, 2013 |
| DEF 14A | Proxy statement | Nov 19, 2012 | Dec 21, 2012 |
| PRE 14A | Preliminary proxy statement | Nov 9, 2012 | Nov 14, 2012 |
| DEFA14A | Additional proxy material | Nov 23, 2011 | — |
| DEF 14A | Proxy statement | Nov 14, 2011 | Dec 22, 2011 |
| DEFA14A | Additional proxy material | Nov 12, 2010 | — |
| DEF 14A | Proxy statement | Nov 12, 2010 | Dec 22, 2010 |
| DEF 14C | Information statement | May 5, 2010 | May 5, 2010 |
| PRE 14C | China pharma holdings, inc. | Apr 1, 2010 | Mar 29, 2010 |
| DEF 14C | Information statement | Sep 23, 2009 | Sep 23, 2009 |
| PRE 14C | Filing | Sep 15, 2009 | Sep 3, 2009 |
| PRE 14C | Filing | Sep 3, 2009 | Sep 3, 2009 |
| DEF 14C | Information statement | Jun 25, 2009 | Jun 25, 2009 |
| PRE 14C | Filing | Jun 22, 2009 | Apr 28, 2009 |
| DEF 14C | Information statement | Jul 11, 2008 | Jul 11, 2008 |
| PRE 14C | Filing | Jun 27, 2008 | Feb 1, 2008 |
| DEF 14C | Information statement | Mar 28, 2006 | Mar 28, 2006 |
| PRE 14C | Ts electronics, inc. - schedule 14c | Jan 25, 2006 | Jan 26, 2006 |
| PRE 14C | Filing | Oct 9, 2003 | Jun 30, 2003 |
| PRE 14C | Filing | Aug 20, 2003 | Aug 20, 2003 |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CPHI (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hainan Province, China
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1106644
- Former names
- TS ELECTRONICS INC (until May 4, 2006); SOFTSTONE INC (until Aug 18, 2003); SOFTSTONE INC /DE/ (until Jan 27, 2003); KILKENNY ACQUISITION CORP (until Mar 30, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.